Sunyu Kang
Harvard University · 14 works · 6,519 citations · h-index 6
Top works
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
- Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab
- Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma
- Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic
- Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab
- R-etodolac is a more potent Wnt signaling inhibitor than enantiomer, S-etodolac
- Pediatric RISE: Development of a Poverty‐Targeted Cash Support Intervention for Pediatric Cancer
- Inadequate social support and household material hardship among children with pediatric acute lymphoblastic leukemia: A report from the Children's oncology group Trial AALL1731
- Out of Reach: Understanding Resource Barriers to Gene Therapy for Pediatric Patients With Sickle Cell Disease
- Pediatric RISE: Development of a Poverty-Targeted Cash Support Intervention for Pediatric Cancer
- Household material hardship as a barrier to accessing sickle cell disease curative therapy
- Feasibility of collecting social determinants of health data in the frontline pediatric acute lymphoblastic leukemia (ALL) trial AALL1731: A report from the Children's oncology group
- 702 dsRNA induces ectopic KRT9 expression via WNT/β-catenin-mediated signaling